Fig. 1: Rapamycin-mediated immune modulation in mice.
Ten B6/129J mice were given AAV9-C-rh 3BNC117 at 0.2 × 1013 GC/kg by the intramuscular (i.m.) route in the absence (MO1 animals #9-13 in blue color) and presence of rapamycin (MO1 animals #14-18 in red color). The treatment group received rapamycin at 2 mg/kg three times a week by the intraperitoneal (i.p.) route for the duration of 12 weeks (week −1 to 11). a ADAs to C-rh 3BNC117 in plasma; upper limit of detection = 4. b C-rh 3BNC117 levels in plasma. c Levels of C-rh 3BNC117 at week 28 post AAV; data are presented as mean values ± SD; mean comparison of the control group (blue circles, n = 5 biological samples) with the rapamycin treatment group (red squares, n = 5 biological samples) using the unpaired t-test (two-tailed) with Welch’s correction, with P ≤ 0.001 (***) indicating statistical significance. d Reactivity to AAV9 capsid in plasma. e Reactivity to AAV9 capsid at week 26 post AAV; data are presented as mean values ± SD; mean comparison of the control group (blue circles, n = 5 biological samples) with the rapamycin treatment group (red squares, n = 5 biological samples) using the unpaired t-test (two-tailed) with Welch’s correction with P ≤ 0.05 (*) indicating statistical significance. Abbreviations: LOD limit of detection. Source data are provided as a Source Data file.
